Remove Biotech Remove Innovation Remove Market Intelligence
article thumbnail

BCG & Hello Tomorrow Track Innovation in Deep Tech Using NetBase Quid

Netbasequid

In their paper on Deep Tech: The Great Wave of Innovation , BCG and Hello Tomorrow explain “what deep tech is, how it works, how different stakeholders can contribute to it, and how it can be harnessed for competitive advantage.” Investment intelligence to inform deep tech understanding. Patents Reveal Emerging Innovations.

Biotech 98
article thumbnail

Key Takeaways from J.P. Morgan’s 41st Annual Healthcare Conference?

Alpha Sense BI

Specifically, within the pharma and biotech sectors, there have been 22 deals announced so far in 2023 — again, a low number compared to the 70 made over the same period last year. Additionally, unprofitable biopharma, aka most biotech companies, is expected to invest $1.1 In 2021, Spinraza sales reached $1.9

Biotech 96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Evolution of AI in Asset Management

Alpha Sense BI

Research shows that the AI in asset management market will grow at a staggering 34% CAGR through 2027. The time is now to invest in a market intelligence platform with AI search capabilities, so you can speed up your research and outperform the market. Artificial intelligence is the only way to do it.

article thumbnail

Slow Start to Venture Capital Funding in 2024

Alpha Sense BI

Below, we explore the factors constraining venture capital funding into the first half of the year, and the ways investors can leverage crucial market intelligence to gain a competitive advantage in the shifting landscape. The VC Funding Dryspell Venture capital investment fell to the lowest activity in nearly five years for Q1 2024.

Capital 69
article thumbnail

Global Precision Medicine Market is Expected to Reach $216.75 billion by 2028

BIS Research

Precision medicine is an innovative approach to prevent and treat diseases by taking into account the individual distinction between genetic make-up, lifestyle, and environment of an individual. It is sometimes also known as personalized medicine. billion in 2018 and is expected to reach $216.75 billion by 2028.

article thumbnail

Venture Capital Trends and Outlook for 2024

Alpha Sense BI

Market Intelligence at Scale : GenAI has the potential to securely pair a company’s internal content with leading premium market content sources using proprietary large language models (LLMs) and genAI trained on both business and financial content. The renewable energy sub-sector is also seeing promising activity.

Capital 52
article thumbnail

Key Takeaways from J.P. Morgan’s 42nd Annual Healthcare Conference?

Alpha Sense BI

We believe that this focus on accessibility and sustainability represents an alternative and attractive opportunity in supporting innovative solutions for global healthcare challenges. This renewed interest in rare disease therapeutics can be attributed to the U.S. Sign up for your free trial today.

Biotech 59